english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Priapism: urgent medical attention required

Priapism, an erection lasting several hours, needs to be diagnosed quickly in order to prevent possibly irreversible erectile dysfunction. It is often caused by medications.
1 September 2020

Drug shortages: a source of errors and adverse events, which should be reported

Drug shortages did not begin with the covid-19 epidemic. Some shortages cause serious harm to patients. Healthcare professionals and patients should report any adverse events related to drug shortages to the competent authorities.
1 September 2020

Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease

 NEWS UPDATE  The detailed results of four comparative trials of hydroxychloroquine in patients with covid-19 were released in late July 2020: two trials in patients hospitalised for covid-19, and two others in patients who were not hospitalised and had milder forms of the disease.
24 July 2020

"Top Texts of 2020", from the editors of Prescrire International

1 March 2021

Covid-19: remdesivir (Veklury°) authorised in the European Union, yet much remains unknown or uncertain

 NEWS UPDATE  The antiviral drug remdesivir was authorised in the European Union in early July 2020 for the treatment of certain adults and adolescents with severe covid-19 requiring supplemental oxygen. It was only granted conditional authorisation, because the data submitted were incomplete on many fronts. The drug company needs to resolve many uncertainties surrounding remdesivir's adverse effects and efficacy.
13 July 2020

Covid-19 and severe breathing problems: dexamethasone reduced mortality in one trial

 NEWS UPDATE  Some detailed preliminary results were released on 23 June 2020 from a randomised trial in patients hospitalised for covid-19 (the “Recovery” trial). Adding the corticosteroid dexamethasone (for up to 10 days) to usual care reduced 28-day mortality in patients receiving oxygen or mechanical ventilation, but appeared unnecessarily dangerous in other patients.
24 June 2020

Andexanet alfa (Ondexxya°) as an antidote to xabans: inadequate clinical evaluation

FEATURED REVIEW The evaluation of andexanet alfa for the management of severe bleeding in patients receiving apixaban or rivaroxaban is inadequate. When bleeding occurs in a patient receiving a xaban, the key action is to put in place proven emergency supportive measures.
Full review (4 pages) available for download by subscribers.
1 July 2020

In the July-August issue of Prescrire International: aflibercept (Eylea°) in diabetic macular oedema without visual impairment

FREE DOWNLOAD What is the efficacy of aflibercept in patients with diabetic macular oedema without visual impairment at the time of diagnosis?
Full text available for free download.
1 July 2020

Proper evaluation, for patients' sake

EDITORIALProper drug evaluation, based on trials designed to provide sufficiently high-level evidence and conclusive results, using patient-relevant clinical outcomes, is the best way of ensuring that drugs are used judiciously, without causing unnecessary harm.
1 July 2020

Pulmonary arterial hypertension: sometimes drug-induced

Many drugs can cause pulmonary arterial hypertension, which sometimes improves when treatment is halted.
1 July 2020

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90